About RX MT2 — Melanotan 2 Research Digest Editorial Mission

About This Site

RX MT2 is an independent editorial project that publishes summaries of the peer-reviewed research literature on Melanotan 2 (MT-II). The compound's research record spans four decades: tanning pharmacology, erectile function trials, central appetite circuitry, neuroprotection, and an expanding pharmacovigilance record. This site organizes and summarizes that record in plain language, with every quantitative claim traced to its source.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier 'RX' in the site name reflects an editorial stance — positioning this site as a reading room for the research, not as a pharmaceutical service. No prescription services, treatment consultations, or clinical recommendations are offered here. The research literature we summarize comes from PubMed-indexed journals, clinical trial records, and peer-reviewed pharmacovigilance publications; we link to primary sources throughout.

What This Site Covers

The Melanotan 2 literature is scientifically interesting for reasons beyond the compound's most publicized application. The serendipitous discovery that an alpha-MSH analog could produce erections in human subjects — documented in Hadley's 2005 historical account^[18] — initiated a research program in central melanocortin pharmacology that ultimately contributed to the development of bremelanotide (PT-141), the first approved drug for hypoactive sexual desire disorder in premenopausal women.

The compound's receptor pharmacology is also the starting point for understanding appetite regulation through the melanocortinergic system, a pathway with implications for metabolic disease. And the pharmacovigilance record — including documented cases of renal infarction, melanoma, and priapism — provides important context for understanding the risks associated with unregulated synthetic peptide use.

This site covers the Melanotan 2 mechanism of action, the clinical trial record, the MT2 dosage protocols studied in research, the Melanotan 2 side effects documented in studies, and the frequently asked questions about the compound. The published references list every source cited across the site.

We do not cover commercial sources, sourcing guides, or product recommendations. Questions of that nature are outside this site's editorial scope.

Editorial Standards

Every quantitative claim on this site is attributed to a specific citation in the references list. No finding is presented without a source. Where the research record is sparse or conflicting, we note it. Where adverse events are documented only in case reports and not confirmed in controlled trials, we say so.

The compound described here — MT-II — is not approved for human use by any regulatory authority. We do not describe it as safe. We do not recommend doses. We describe what was administered to which species at which dose in which study, and what was measured.

This is what an independent editorial research digest looks like: the primary sources, rendered in plain language, without the marketing frame of a vendor or the overcautious hedging of an institution with liability to manage.